• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[머니투데이] 큐로셀, 국산 첫 CAR-T 치료제 상용화 초읽기…’기적의 항암제’ 넘어 시장 약속 지킬까

2024/12/05

큐로셀, 국산 첫 CAR-T 치료제 상용화 초읽기…’기적의 항암제’ 넘어 시장 약속 지킬까 – 머니투데이

Prev큐로셀, 사업 담당에 이승원 상무 영입… “안발셀 상업 가속화”
Next큐로셀 CAR-T 치료제 ‘안발셀’, 허가-평가-협상 병행 2호 선정
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.